Brain imaging to personalize antipsychotic treatment for psychosis
Part of Hormones & metabolism, Mental health clinical trials.
This study uses brain scans (MRI) to compare how different antipsychotic medications work in people with psychosis. The goal is to find the best treatment for each person, which could lead to more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a patient at the PEP clinic in Estrie (a clinic for early psychosis), either as an outpatient or in the hospital.
- You must be willing to start taking an antipsychotic medication (this trial will not supply the drug).
- You must be able to read and speak French or English, and be able to give informed consent.
- You cannot have taken antipsychotics for more than 2 weeks in the last year, or more than 6 weeks in your lifetime (except for some very low doses).
- You must not have any metal in your body that would make an MRI unsafe.
- This trial is not for people with certain other conditions, like psychosis with borderline personality disorder, autism, severe substance use problems, medical or drug-induced psychosis, type 1 diabetes, or uncontrolled suicidal thoughts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a brain scan called magnetoencephalography (MEG) to understand brain activity in people with schizophrenia. It may help researchers learn more about the condition and could lead to better treatments.
This study uses brain scans to find markers that can predict how well antipsychotic medications work in people having their first episode of psychosis. It aims to help doctors choose the right treatment earlier.
This study looks at whether special body and brain markers can predict how a person’s symptoms change over two years after a first psychotic episode. It may also help doctors understand who responds better to treatment, so future care can be more personalized.
This study uses brain imaging to look at dopamine activity in people at high risk for psychosis. The results may help improve future treatments.
This study looks at how a specific type of brain receptor (dopamine-3) works in people with schizophrenia using special brain scans (PET). Researchers want to see how these receptors behave when you are not taking antipsychotic medication, which may help guide future treatments.
This study tests whether using brain scans and genetic tests can help choose the best treatment for people early in their schizophrenia. It will check if these biomarkers can predict who will respond better to medication.
Hear when a new Metabolic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.